Reinventing the fight against bacteria, one phage at a time.

🧬 Temporary Pause on The Phage Therapy Dear readers, Due to important academic deadlines for part of our team, activity on thephagetherapy.blogspot.com,  will be temporarily paused. We’ll resume posting in mid-December , with fresh articles and deeper insights into phage research and applications. In the meantime, take this opportunity to revisit our previous articles — they’re full of exciting content about phage therapy, current research, and new developments in the field. Thank you for your understanding and continued support 💫 — The Phage Therapy Team Photo taken from :  https://teachlikeachampion.org/blog/pause-points-a-clip-from-sara-sherrs-online-classroom/

The European Medicines Agency Publishes Draft Guideline on Quality Aspects of Phage Therapy Medicinal Products: A Landmark in the Regulation of Bacteriophage Therapeutics Introduction On 16 October 2025 , the European Medicines Agency (EMA) , through its Committee for Medicinal Products for Human Use (CHMP) and the Biologics Working Party (BWP) , adopted for public consultation the draft Guideline on Quality Aspects of Phage Therapy Medicinal Products (EMA/CHMP/BWP/1/2024) . This 15-page document represents the first comprehensive regulatory framework in the European Union specifically addressing the quality, manufacturing, and control requirements for bacteriophage-based medicinal products intended for human use. The release of this draft guideline is a significant milestone in the development of phage therapy as a legitimate, standardised, and potentially widely accessible treatment modality for bacterial infections, particularly in the context of the global antimicrobial resi...

Upcoming Event — Phage Therapy Against Superbugs: Towards Real World Implementation The Graduate School of Medicine at Osaka Metropolitan University will host the international symposium, “Phage Therapy Against Superbugs: Towards Real World Implementation”, to commemorate the opening of Morinomiya Campus. In recent years, due to the spread of Antimicrobial-resistant bacteria, phage therapy—using viruses that infect bacteria—has gained worldwide attention. This symposium invites leading researchers from UC San Diego, one of the centers for clinical trials of phage therapy in the United States, to share cutting-edge insights. If you are interested, please feel free to join us.   Event Details Date & Time:   Saturday, November 8, 2025, 10:00 a.m.–12:00 p.m. Venue:  Auditorium, 3rd Floor, Morinomiya Campus Language:  English Capacity:  400 Registration:  Free / Register online by November 7 Registration Form Program   Lecture “Current Status of Phage T...

Consultation: Proposed GMP exemption for certain bacteriophage manufacture Overview Taken from :  https://walyanrespiratory.thekids.org.au/projects/phage-wa/helpful-links/ The Therapeutic Goods Administration (TGA) is seeking your feedback on a proposed time-limited GMP exemption for manufactures of personalised bacteriophage therapy products (BTPs).  In the last 5-10 years, increasing anti-microbial resistance (AMR) and medical device-related infections have led to the resurgence in interest from researchers and clinicians seeking access to experimental therapies for their patients. Unapproved BTPs are increasingly being considered. However, BTPs have not had their efficacy, safety or quality assessed by the TGA and are currently being supplied as unapproved goods under the Special Access Scheme (SAS) and Clinical Trial Notification (CTN) scheme provisions. The manufacturing process of BTPs is multifaceted and complex and there are no Good Manufacturing Practice (GMP) license...

New Wellcome Trust funding for Imperial Life Sciences and Medicine research view large Electron microscopy micrographs showing chimeric cf-PICIs Funding has been awarded to investigate the mechanisms driving bacterial evolution and explore novel strategies to combat antibiotic resistance. A team of Imperial scientists from Life Sciences and Medicine have received approximately £2.7 million through the  Wellcome Trust Discovery Award . The research focuses on capsid-forming phage-inducible chromosomal islands (cf-PICIs), a recently discovered mechanism by which bacteria exchange DNA across species. Cf-PICIs release small, tail-less capsids that can later acquire phage tails from unrelated bacteria, creating chimeric particles capable of transferring virulence and antibiotic resistance genes. "This recognition validates the importance of our discoveries on bacterial evolution and gives us the resources to take the next step: translating them into tangible advances against antibiotic...

Antibiotic resistance: the crazy project of the Hospices Civils de Lyon against superbugs By  Camille Dubois  Health Journalist Written on 10/14/2025 Antibiotic resistance is now reaching proportions unimaginable even twenty years ago. Every year, doctors see the emergence of infections that they once struggled to treat due to a lack of effective drugs. Faced with this impasse, researchers are exploring other avenues. Among them, an old method is making a comeback: phage therapy. The idea seems simple, almost elegant: using viruses that attack only bacteria. In Lyon, a team recently published encouraging results, suggesting a credible alternative to conventional treatments. Summary An out-of-control phenomenon Breathless treatments A fragile but real hope An out-of-control phenomenon The figures are stark. According to the World Health Organization, more than 23 million infections have been recorded in 104 countries. And the findings are stark: one in six bacterial infections ...

PARADIGM – Personalised phAge therapy against gRam-negAtive multiDrug resIstant orGanisMs The PARADIGM project (project ANR-24-PEBI-0005) is part of the France 2030 plan and was selected by the French National Research Agency (ANR) via its Priority Research Programs and Equipment initiative on Biotherapies – PEPR Biothérapies. The project is led by Paris Public Hospital Network (Assistance Publique des Hôpitaux de Paris, AP-HP), in partnership with the Biological Resource Center of Institut Pasteur ( CRBIP ) and the French Alternative Energies and Atomic Energy Commission (Commissariat à l’énergie atomique et aux énergies alternatives, CEA). Given the health emergency represented by antibiotic resistance, the aim of the PARADIGM project is to support personalized phage therapy development in France against, in principle, two priority multidrug-resistant pathogens:  Escherichia coli  and  Klebsiella pneumoniae . Bacteriophages, or phages, are viruses capable of infecting a...